Neurofarmacología de la ingesta y la conducta adictiva
Instituto de Química Médica
Madrid, EspañaInstituto de Química Médica -ko ikertzaileekin lankidetzan egindako argitalpenak (18)
2023
2021
2015
-
Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation
Journal of Medicinal Chemistry, Vol. 58, Núm. 16, pp. 6639-6652
2014
-
CB1 blockade potentiates down-regulation of lipogenic gene expression in perirenal adipose tissue in high carbohydrate diet-induced obesity
PLoS ONE, Vol. 9, Núm. 2
-
Combining rimonabant and fentanyl in a single entity: Preparation and pharmacological results
Drug Design, Development and Therapy, Vol. 8, pp. 263-277
2013
-
Description of a bivalent cannabinoid ligand with hypophagic properties
Archiv der Pharmazie, Vol. 346, Núm. 3, pp. 171-179
-
Ghrelin-Induced Orexigenic Effect in Rats Depends on the Metabolic Status and Is Counteracted by Peripheral CB1 Receptor Antagonism
PLoS ONE, Vol. 8, Núm. 4
-
Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21
Bioorganic and Medicinal Chemistry, Vol. 21, Núm. 7, pp. 1708-1716
2012
-
Anti-obesity efficacy of LH-21, a cannabinoid CB 1 receptor antagonist with poor brain penetration, in diet-induced obese rats
British Journal of Pharmacology, Vol. 165, Núm. 7, pp. 2274-2291
-
Elaidyl-sulfamide, an oleoylethanolamide-modelled PPARα agonist, reduces body weight gain and plasma cholesterol in rats
DMM Disease Models and Mechanisms, Vol. 5, Núm. 5, pp. 660-670
-
Obesity and the Endocannabinoid System: Is There Still a Future for CB1 Antagonists in Obesity?
Current Obesity Reports, Vol. 1, Núm. 4, pp. 216-228
2011
-
Discovery of potent dual PPARα agonists/CB1 ligands
ACS Medicinal Chemistry Letters, Vol. 2, Núm. 11, pp. 793-797
2009
-
Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide
European Journal of Medicinal Chemistry, Vol. 44, Núm. 12, pp. 4889-4895
2008
-
Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents
Bioorganic and Medicinal Chemistry, Vol. 16, Núm. 23, pp. 10098-10105
-
Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: Effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats
Journal of Neuroendocrinology
2007
-
Novel sulfamide analogs of oleoylethanolamide showing in vivo satiety inducing actions and PPARα activation
Journal of Medicinal Chemistry, Vol. 50, Núm. 2, pp. 389-393
2006
-
Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole - LH 21
Neuropharmacology, Vol. 51, Núm. 2, pp. 358-366
2004
-
Discovery of 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif
Journal of Medicinal Chemistry, Vol. 47, Núm. 11, pp. 2939-2942